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Abstract
Background and Aims—Studies of the prognostic value of Ishak fibrosis stage are lacking.
We utilized multi-year follow-up of the Hepatitis C Antiviral Long Term Treatment Against
Cirrhosis (HALT-C) Trial to determine whether individual Ishak fibrosis stages predicted clinical
outcomes in patients with chronic hepatitis C.
Methods—Baseline liver biopsies from 1,050 patients with compensated chronic hepatitis C who
had failed combination peginterferon and ribavirin were reviewed by a panel of expert
hepatopathologists. Fibrosis was staged with the Ishak scale (ranging from 0=no fibrosis to
6=cirrhosis). Biopsy fragmentation and length as well as number of portal tracts were recorded.
We compared rates of pre-specified clinical outcomes of hepatic decompensation and
hepatocellular carcinoma across individual Ishak fibrosis stages.
Results—Of 1,050 biopsies 25% were fragmented, 63% >1.5 cm, 69% >10 mm2, and 75% had
≥10 portal tracts. Baseline laboratory markers of liver disease severity were worse and the
frequency of esophageal varices higher with increasing Ishak stage (p<.0001). The six-year
cumulative incidence of first clinical outcome was 5.6% for stage 2, 16.1% for stage 3, 19.3% for
stage 4, 37.8% for stage 5, and 49.3% for stage 6. Among non-fragmented biopsies, the predictive
ability of Ishak staging was enhanced; however, no association was observed between Ishak stage
and outcomes for fragmented biopsies due to high rates of outcomes for patients with non-
cirrhotic stages. Similar results were observed with liver transplantation or liver-related death as
the outcome.
Conclusions—Ishak fibrosis stage predicts clinical outcomes, need for liver transplantation, and
liver-related death in patients with chronic hepatitis C. Patients with fragmented biopsies with low
Ishak stage may be understaged histologically
Keywords
fibrosis; cirrhosis; hepatitis C; liver biopsy; fragmentation
Liver biopsy remains the accepted standard for histologic assessment of liver disease
activity and fibrosis, despite such limitations as sampling variability, potential complications
of an invasive technique, and subjective scoring. Studies of the natural and treatment-
modified histologic progression of liver injury and fibrosis have relied upon the adoption of
uniform grading and staging criteria.(1) With the availability of semi-quantitative
measurements, investigators have been able to deduce relative rates of histologic
progression and to go well beyond the qualitative information available from liver biopsies.
Although several histologic scoring systems are used widely in clinical research, prospective
studies of the prognostic value of staging of fibrosis— i.e., of the correlation between the
fibrosis stage and subsequent outcomes or complications of liver disease—are rare.(2)
Among patients with established cirrhosis, clinical complications of chronic liver disease,
such as ascites, variceal bleeding, hepatic encephalopathy, coagulopathy, and renal/
electrolyte disorders, emerge progressively over time; however, it has not been shown
whether the sequential stages of fibrosis (short of cirrhosis) identified by these grading
systems predict a higher likelihood of the clinical consequences of chronic liver disease.
Of the scoring systems described in the literature, the most commonly used in the United
States are the Knodell histologic activity index (0–4), Batts-Ludwig stage (0–4) and Scheuer
(0–4) (3–5) and the METAVIR scheme (0–4) in Europe.(6) The Ishak staging system, which
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has not enjoyed the general popularity of the others, is a modification of the Knodell system
(which lacks a stage 2) and has six stages of fibrosis (0–6).(7) In recent years, the Ishak
staging system has become widely used in clinical trials, especially in the United States.
Because each Ishak fibrosis stage reflects more scarring than the preceding stage, clinicians
and investigators assume that succession from one stage to the next represents progressively
more advanced liver disease.
Thus, patients with a higher stage should have an increasing risk of clinical outcomes if each
score compared to its lower counterpart represents a significant difference in disease
severity. However, the link between fibrosis stages and clinical outcomes has not been
validated in a prospective trial.
The HALT-C Trial provided an opportunity to follow prospectively more than 1,000
patients for up to 6 years and to assess the association of Ishak fibrosis stage and clinical
outcomes. Moreover, because no difference in clinical outcomes occurred between the
maintenance peginterferon-treated and untreated-control arms, the two arms could be
combined, doubling the number of subjects for analysis. The demonstration of a stepwise
increase in the frequency of clinical outcomes with each increase in histologic fibrosis stage
among pre-cirrhotic and cirrhotic patients would help establish the validity of multiple
fibrosis staging levels as reflected in the Ishak scoring system.
METHODS
The HALT-C Trial study design and main results have been described in detail.(8, 9)
Briefly, 1,050 patients with compensated liver disease related to hepatitis C-related (that is
Child- Turcotte-Pugh [CTP] score of 5 or 6), who had not had a sustained virological
response to an adequate course of peginterferon and ribavirin were randomized to receive
maintenance therapy with peginterferon alfa-2a in a dose of 90 µ g per week or no treatment
for 3 and a half years. Written informed consent was obtained from each patient, and the
protocol had a priori approval by the institutional review committee of each participating
center. All patients had local histological interpretation of protocol biopsies by individual
study pathologists followed by central reading (see below). Fibrosis was staged according to
the Ishak fibrosis scale of 0 to 6.(1, 7, 10) In this system, a score of 2 is defined as fibrous
expansion of most portal areas, with or without short fibrous septa; 3 fibrous expansion of
most portal areas with occasional portal-to-portal bridging; 4 fibrous expansion of most
portal areas with marked bridging (both portal-to-portal and portal-to-central); 5 incomplete
cirrhosis characterized by marked bridging and occasional nodules; and 6 probable or
definite cirrhosis. To enter the trial, a study participant had to have had a current or a past
liver biopsy interpreted by the local clinical-site study pathologist as demonstrating an Ishak
fibrosis score of 3 or greater. A subsequent central reassessment of the biopsy through a
consensus evaluation at a multiheaded microscope by the pathology reading group
(composed of pathologists from the individual centers) could result in a change of the stage.
By the conclusion of the central reading process, 79 baseline biopsies were scored as stage
2; 53 of these biopsies had been scored as 3 or greater when interpreted at the local site, and
26 were from patients whose current biopsies were staged locally as 2 but who had had an
earlier biopsy scored as stage 3 or greater. The central, not the local, reading has been used
to establish the fibrosis stage for all HALT-C Trial manuscripts, including this one.
According to the HALT-C Trial protocol, the biopsy required for study entry and
stratification into the bridging fibrosis group versus the cirrhosis group could have been
performed as long as 12 months prior to the baseline clinical visit and as long as 2 years
prior to randomization for a few patients who had virological relapse after a full course of
therapy.(8)
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Due to the difficulty in interpreting the severity of fibrosis correctly from an inadequate
biopsy, we also examined characteristics of biopsy quality. Biopsy length was determined at
the time of central reading. For two ancillary studies, total biopsy area was measured on
1,004 baseline biopsies and number of portal tracts recorded on 1,002 biopsies. Biopsy
fragmentation was determined by a single study pathologist, who judged as fragmented
multiple small pieces of tissue with rounded contours, usually not more than 2 mm in size.
When two biopsy passes had been made with one fragmented and the other not fragmented
(of reasonable size), the biopsy was categorized as non-fragmented. Examples of fragmented
biopsies are shown in Figure 1.
Following the conclusion of the randomized phase, HALT-C participants continued
scheduled semi-annual visits that included ascertainment of study outcomes. For this
analysis, the first liver-related clinical outcome within 6 years of randomization was used as
the primary endpoint. About 80% if the original cohort who had not had a primary outcome
continued to be seen through 6 years. Because treatment had no impact on clinical
outcomes,(9) we grouped treated and untreated-control subjects together. The predefined
primary clinical outcomes included an increase in CTP score to at least 7 on two successive
study visits at least 3 months apart, ascites, encephalopathy, bleeding esophageal or gastric
varices, hepatocellular carcinoma, or death. For these analyses, however, we excluded
deaths that were considered to be unrelated to liver disease. Secondary outcomes included
liver transplantation and liver-related death.
Statistical methods
We compared rates of predefined liver-related clinical outcomes across Ishak fibrosis stages.
Cumulative incidence over time of outcomes were calculated with Kaplan-Meier survival
estimates and comparison of outcomes by fibrosis stage with the Cox proportional hazards
model. Results are reported as hazard ratios (HR) and 95% confidence intervals. Stage 2 and
3 cases were not compared by Cox analysis because of the small number of events for
patients with stage 2 and because the model assumption of a constant HR across time could
not be met.
Analysis of variance, logistic regression, and the chi-square test for trend were used to
assess the relationship between biopsy characteristics, demographic and laboratory
variables. SAS version 9.1 was used for all analyses (SAS Institute, Cary, NC), and a p
value of < 0.05 was considered to be statistically significant. No adjustments were made for
multiple comparisons.
RESULTS
A total of 1,050 patients were eligible to be followed for clinical outcomes. The mean (±
standard deviation) time from biopsy to randomization was 269 ± 177 days, uniform across
all Ishak fibrosis stages, except for Ishak stage 4, which was longer at 303 ± 175 days (Table
1). Similar proportions of patients were randomized to treatment across Ishak scores
(p=0.55). Several characteristics of the biopsies were examined in addition to Ishak stage.
Sixty-three percent of biopsies were at least 1.5 cm long, 69% had an area of at least 10
mm2, and 75% contained at least 10 portal triads; none of these biopsy characteristics varied
substantially across Ishak score (test for trend, p >0.10). Among the biopsy characteristics,
fragmentation was associated most strongly with Ishak stage (p=0.0002), occurring more
commonly among patients with cirrhosis.
Mean ± SD time from biopsy to enrollment laboratory testing was 94 ± 137 days and did not
differ by Ishak fibrosis stage (test for trend, p-value =0.47) (Table 1). Laboratory markers
that reflect severity of liver disease (lower platelet count and albumin; higher AST/ALT
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ratio, bilirubin, and INR ) and the frequency of esophageal varices were increased
proportionately to increased Ishak stage (p<0.0001 for all these variables). These trends
were examined further according to whether or not the biopsy was fragmented. Patients with
fragmented biopsies had lower platelet counts than those with non-fragmented biopsies
(p<0.0001). In addition, the decline in platelet count with increasing Ishak stage was steeper
among patients with non-fragmented biopsies than among patients with fragmented biopsies
(test for interaction, p<0.0001). AST/ALT ratio (p=0.06), total bilirubin (p=0.02), and INR
(p=0.001) were higher, and albumin (p=0.17) was slightly lower for the fragmented than
non-fragmented biopsies, but the interaction with Ishak score was not statistically significant
for AST/ALT ratio (p=0.09), bilirubin (p=0.05), and albumin (p=0.32), yet was for INR
(p=0.01). The prevalence of esophageal varices was higher for patients with fragmented
(31.1%) than non-fragmented biopsies (24.0%) (p=0.001). As was the case for platelets and
INR, the prevalence of varices was higher in patients with fragmented than with non-
fragmented biopsies across Ishak stages, especially for Ishak stages 2 and 3 (test for
interaction p-value = 0.02).
Prognostic significance of Ishak fibrosis score on primary outcomes
The cumulative 6-year incidence of a first clinical outcome was 27.0% for all patients and
ranged from 5.6% for Ishak stage 2 to 49.3% for Ishak stage 6 (Table 2 and Figure 2a). For
patients with an Ishak stage of 6, clinical events began to occur shortly after randomization
and rose by about 8% per year (Figure 2a). A progressive lag in events was observed for the
patients with lower stage disease, most pronounced for patients with an Ishak fibrosis stage
of 2, none of whom had an event until nearly 5 years after randomization (and only three
after that). When the rate of clinical outcomes was compared for each Ishak stage with the
rate for the next lower stage, the outcome rate was statistically significantly higher for Ishak
6 compared with Ishak 5, for Ishak 5 compared with Ishak 4, but not for Ishak 4 compared
with Ishak 3 (top of Figure 3). Treatment assignment had no effect on the results.
Effect of fragmentation on first primary outcome
The same analysis was performed according to whether or not the biopsy was fragmented.
The cumulative, 6-year incidence of clinical liver-disease outcomes according to baseline
Ishak fibrosis stage and fragmentation is shown in Figure 2b (non-fragmented) and 2c
(fragmented). Overall, patients with fragmented biopsies were more likely to have clinical
outcomes than patients with non-fragmented biopsies (HR = 1.9; 95% CI = 1.4–2.4);
however, this observed difference in clinical outcomes was confined to patients with Ishak
fibrosis stages 3 and 4. Thus, at Ishak stages less than 5, fragmentation was associated with
increased rates of outcomes, a finding not seen in patients with cirrhosis, stages 5 and 6 (test
for interaction, p<0.0001). In the comparison of rates of outcomes between one Ishak stage
and the next lower stage, the hazard ratios were statistically significant for patients with non-
fragmented biopsies (Figure 3) (test for trend p<0.0001). Specifically, when we compared
the rate of clinical outcomes for each Ishak fibrosis stage with the rate for the next lower
stage, we found that the outcome hazard ratio for each comparison was higher for patients
with non-fragmented biopsies than with fragmented biopsies (Figure 3). If the biopsy was
fragmented, only a borderline association of Ishak stage with outcomes was observed (test
for trend, p=0.05). This association was a result of a modest prognostic value (HR = 1.6;
95% CI= 1.004–2.4, p=0.05) for the presence of cirrhosis (Ishak stage 5 or 6) relative to the
presence of less severe fibrosis (Ishak stage 4 or less)
Other markers of biopsy quality
Other markers of biopsy quality did not have an appreciable influence on the results. Thus,
in general, patients with longer biopsies, larger biopsy areas, or more numerous portal tracts
did not have different rates of outcomes than patients with lower quality biopsies (Table 2).
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The only exception was biopsy length among patients with an Ishak fibrosis stage 5; in this
single subset, patients with biopsy length of <1.5 cm had cumulative outcomes of 53.5%
versus a cumulative incidence of 28.5% among patients with longer biopsies (p=0.0003).
Unlike fragmentation, these measures of biopsy quality did not interact significantly with
Ishak stage in relation to outcomes.
Prognostic significance of Ishak fibrosis stage for liver transplantation or liver-related
death
Nearly half of all first clinical events (48.3%) were increases in CTP score to 7 or more,
primarily achieved through deterioration in laboratory components of the score (albumin,
bilirubin and prothrombin time/INR). To assess the impact of Ishak fibrosis stage on
secondary clinical outcomes of liver transplantation and liver-related deaths, the same
analyses were performed as described above for primary clinical outcomes. Sixty-eight
patients underwent liver transplantation, and another 58 patients died from liver disease
without liver transplantation (half from end-stage liver disease and half from hepatocellular
carcinoma). The cumulative 6- year incidence of these outcomes was 14.3%. As was the
case for primary clinical outcomes, there was a strong association between successive Ishak
fibrosis stages and liver-related death and liver transplantation (Figure 4a and Table 3). In
individual comparisons between fibrosis stages, there was a statistically significant
difference in secondary clinical outcomes between Ishak 4 (marked bridging but no nodules)
and 5 (bridging with occasional nodules), but not for 3 (occasional bridging) versus 4 or 5
versus 6 (cirrhosis) (Figure 3, lower half). As with the primary outcomes, there was an effect
of fragmentation on the association between Ishak stage and outcome (Figure 4b and 4c)
(test for interaction, p=0.0005). This effect was most striking with Ishak stage 3; for this
subgroup, if the biopsy was fragmented, the frequency of liver-related death or liver
transplantation was nearly as high as that for patients with stage 6.
Complexities of the HALT-C Trial design that could have affected the results
Two design issues of the HALT-C Trial that could have affected the results were examined:
1) the difference in time between the initial biopsy and the beginning of observation for
clinical outcomes and 2) randomization assignment to treatment or control. From the date of
the initial baseline biopsy, the time when observation for clinical outcomes began varied
widely, ranging from 10 to 918 days. Because only patients who did not have an outcome
between the baseline biopsy and randomization could be followed for clinical outcomes, we
could not determine directly whether the variable delay between biopsy and randomization
could have affected the results, and patients with cirrhosis did have a trend to shorter biopsy-
to-randomization interval (test for trend, p=0.05, Table 1). When we compared outcomes for
patients whose randomization date was either > or ≤200 days (close to the median of 198
days), the trend to more frequent outcomes with increasing Ishak stage was not affected by
the time to randomization (Table 2). Overall, when we controlled for Ishak stage, patients
with longer times between the baseline biopsy and randomization had a statistically
insignificant lower rate of outcomes (HR 0.79, 95% CI 0.61–1.03, p=0.08) than patients
with shorter biopsy-to-randomization times. This observation was most apparent for patients
with Ishak 3 stage (Table 2); however, in light of the fact that the rate of clinical outcomes
within a year of randomization for Ishak stage 3 was only 1.7%, the delay prior to
randomization was unlikely to have substantially affected the results. Most important, no
marked evidence was apparent for an interaction of time to randomization with Ishak stage
on outcomes (p=0.08). Similarly, because randomization was based on fibrosis stratum
(precirrhotic fibrosis group versus cirrhosis group), no statistically significant difference in
Ishak stages was observed between treated and untreated patients (Table 1, p=0.55), and
treatment had no effect on outcomes (p=0.75). Thus treatment did not appear to influence
the relationship between Ishak fibrosis stage and outcomes (test for interaction, p=0.53).
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DISCUSSION
In designing this study, we pursued two principal questions: 1) do the individual Ishak
fibrosis stages have prognostic value, and 2) does consideration of the presence of liver-
biopsy tissue fragmentation enhance the staging of bridging fibrosis? Our analysis indicates
that the answer to both questions is yes.
Numerical scoring systems for evaluating liver biopsies came into widespread use in clinical
trials in the 1990s as new treatments for hepatitis B and C were developed. The four systems
used most often are the Knodell score,(3) which has only three stages of fibrosis (portal,
bridging, and cirrhosis), the Batts-Ludwig and Scheuer(4, 5) with four stages (portal,
periportal, septal with nodularity and cirrhosis) and METAVIR,(6) with four stages (portal,
few septa, numerous septa, and cirrhosis). The Ishak system,(7) with six stages of fibrosis,
has been used less often, but, because of its finer distinctions of fibrosis and architectural
remodeling, we chose the it as the primary system for the HALT-C Trial. Therefore, the
current analysis addressed the issue of whether, in fact, the Ishak fibrosis staging system
provided clinically useful prognostic information.
More than 100 papers have been published on the natural history of and prognostic factors in
patients with cirrhosis resulting from hepatitis C and other liver diseases.(11) Only a few
studies have incorporated numerical scoring systems to assess fibrosis progression in
repeated liver biopsies to estimate rates of fibrosis progression to cirrhosis in hepatitis C.
(11–17) To our knowledge, however, in only one study have investigators examined the
utility of a contemporary fibrosis scoring system (the Ishak system) along with other clinical
and laboratory factors in predicting clinical outcomes in patients with chronic hepatitis C.
(18) In that single-region study, 131 clinically compensated patients with advanced fibrosis,
defined as Ishak stages 4 (marked bridging) to 6 (cirrhosis), were followed for a median of
51 months, during which 25% died or underwent liver transplantation. The authors did not
find an association of Ishak stage with prognosis, but the sample was much smaller than that
of the HALT-C Trial (for example, only 26 patients had Ishak fibrosis stage 4), and deaths
were not restricted to those related to liver disease. In contrast, in the present study of 1,050
patients who were followed clinically for up to 6 years, we found statistically significant
differences between successive Ishak stages 4 through 6 for the likelihood of developing
clinical outcomes. Overall, when all study patients were assessed, we observed no
significant difference in clinical outcomes between patients with stages 3 (occasional
bridging) and 4 (marked bridging); however, in patients with baseline biopsies interpreted as
stage 3, those with fragmented biopsies had both indicators of poorer liver function and
portal hypertension and much higher rates of outcomes than patients with non-fragmented
stage 3 biopsies. A reasonable inference is that many of the fragmented stage 3 biopsies
were understaged and actually cirrhotic. Excluding fragmented biopsies from the analysis,
we found that the difference in outcomes between stages 3 and 4 was much closer to
achieving statistical significance (Figure 3). These findings reflect the difficulties for
pathologists in interpretation of biopsies that are not intact cores. The pathologist cannot
assume that fragmentation equals cirrhosis; rather, he or she evaluates the amount of
collagen present as well as other subtle features of cirrhotic remodeling. In very small and
fragmented biopsies, there may be very little of either.
A confident histologic diagnosis of cirrhosis requires remodeled vascular architecture as
assessed by the observation of nodules of hepatocytes surrounded by fibrous tissue.(19) In
the absence of this direct criterion, fragmentation of a biopsy specimen obtained by suction
biopsy technique has been recognized to provide strong suggestive evidence that the patient
may have underlying cirrhosis;(20) therefore, especially in this setting, correlation with
clinical and laboratory findings can help establish a clinical-pathologic diagnosis of
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advanced liver disease with probable cirrhosis.(19, 21, 22) To prevent bias in clinical trials,
however, histologic reviews must be blinded to clinical information and laboratory findings
and different biopsy techniques from various centers cannot be avoided. Accordingly, even
though a fragmented biopsy is suspicious for cirrhosis, unless the specimen contains at least
some fragments surrounded by a thin rim of fibrous tissue, the patient’s fibrosis stage will be
underscored. The fact that specimen fragmentation introduces a systematic source of error in
liver biopsy interpretation emphasizes the need for use of standardized biopsy techniques in
clinical trials to avoid this problem. For studies of fibrosis, liver biopsies obtained with
cutting biopsy needles have been shown to be superior to those obtained with suction
needles and are more likely to yield the correct diagnosis of cirrhosis.(23–25)
The current findings have an important implication for the design of clinical trials of new
forms of therapy for hepatic fibrosis and remodeling. The six-stage Ishak system
distinguishes between early or incomplete cirrhosis and established or advanced cirrhosis,
but the other histologic scoring systems do not. Our results show that the difference between
early or incomplete (stage 5) cirrhosis and established (stage 6) cirrhosis is clinically
significant; therefore, in trials of antifibrotic therapy, the Ishak system can be considered
superior to other systems that do not include this distinction.
The implications of our findings extend to clinical practice. When reporting the results of
liver biopsies obtained from patients with chronic hepatitis C, many pathologists provide
histologic stage on a limited scale of only 0 to 4; biopsies consistent with cirrhosis, whether
early or advanced, are categorized as being stage 4 in the scoring systems in most common
use. In clinical practice, whether fibrosis is staged on a limited 4-point or more finely
discriminative 6- point scale, a more meaningful and precise pathology report should include
an accompanying narrative that states whether the cirrhosis is early or incomplete or
established, which are more precise distinctions that carry prognostic implications for the
patient. In such clinical settings, the narrative is superior to and conveys more meaningful
information than a simple numerical stage.
Although our data allow us to conclude that, in the absence of tissue fragmentation, Ishak
fibrosis stages of 3, 4, 5 and 6 represent clinically progressive liver disease, a limitation of
this study is the small number of patients with Ishak stages of 2 or less. In the HALT-C
Trial, only patients with advanced hepatic fibrosis were enrolled in order to include a
population in which clinical outcomes could be anticipated during the period of monitoring;
the rate of clinical progression in patients with milder degrees of fibrosis would have been
too low for this assessment. Therefore, studies of serial biopsies over time in patients with
mild fibrosis will be necessary to determine if prognostic information can be derived from
early as well as from late Ishak fibrosis stages. Nevertheless, in the HALT-C trial, patients
with Ishak fibrosis stage 2 had no clinical outcomes until nearly 5 years after randomization
(Figure 2) and closer to 6 years after the baseline biopsy.
Thus in patients with advanced hepatic fibrosis, the Ishak fibrosis stage provides
prognostically meaningful distinctions between and among stages in technically adequate,
non-fragmented biopsy specimens. Attempts to optimize specimen quality and to avoid
tissue fragmentation will improve the accuracy and value of fibrosis scoring. Alternatively,
if fragmentation has occurred and is accompanied by pertinent clinical and laboratory
findings, then there is a high likelihood of cirrhosis (stage 6). Such patients need more
accurate assessments of disease severity and appropriate follow-up surveillance for
development of hepatic decompensation and hepatocellular carcinoma.
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Figure 1.
Examples of fragmented biopsies. Specimen on left, which only has fibrosis focally along
the edge of one fragment, was interpreted as Ishak stage 3. Specimen on right has fibrosis
enveloping several fragments and was interpreted as Ishak stage 6.
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Figure 2.
Cumulative, 6-year incidence of first clinical liver disease outcome according to baseline
Ishak fibrosis stage. a) all (non-fragmented and fragmented) biopsies, b) non-fragmented
biopsies and c) fragmented biopsies.
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Figure 3.
Hazard rate ratios and 95% confidence intervals for clinical outcomes over 6 years for Ishak
fibrosis stage relative to the next lower stage.
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Figure 4.
Cumulative incidence of transplantation or liver related death according to baseline Ishak
fibrosis stage. a) all (non-fragmented and fragmented) biopsies, b) non-fragmented
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